Cel Monoclonal antibodies (mAbs) represent a new form of protein-based drug having demonstrated a significant impact on the treatment of several types of cancers.Their specificity towards cell surface receptors makes them able to target and destroy tumour cells. However, a lot of progress is still necessary to understand the mechanism of binding and activity of antibodies in order to improve their targeting capabilities and their efficiency.To reach these objectives, the BMC project proposes to:- Develop a recombinant bispecific mAb with tetrameric binding sites, directed against two different antigens expressed on the same target tumour cell;- Develop new bispecific or bifunctional molecules with the property of crosslinking two different receptors on the surface of the cell;- Modify the carbohydrate moiety of bispecific antibodies and the tumour targeting of the complement regulator molecule, properdin, to trigger the activation of the complement enzymatic cascade at the tumour site.The recombinant molecules are directed against a selected target antigen for mAb therapy, CDS, as well as a B-cell marker to be selected, in order to treat a specific type of leukaemia, the B-CLL. However, the described innovative cancer immunotherapy strategy will also be extended to the treatment of many other types of cancers especially all carcinomas.The partnership gathers 9 partners recovering the needs of the BMC project:- 7 RTDs specialized in genetic engineering (CNRS), innovative molecules design (UNIL), antibodies vectorisation with nanoparticles (HUJI), CDC activity improvement and cell lines and animal models development (GIENSAT), mechanisms of therapeutic antibodies on patients' cells (OORRBG), toxicology studies and standardization (ITEM);- 2 biotechnology SMEs specialized in therapeutic antibodies development (MAT) and antibodies in-vitro production (MABGENE);- A company dedicated to the project management until month 50: ALMA. Dziedzina nauki medical and health sciencesmedical biotechnologygenetic engineeringnatural sciencesbiological sciencesbiochemistrybiomoleculescarbohydratesmedical and health sciencesbasic medicineimmunologyimmunotherapymedical and health sciencesclinical medicineoncologyleukemiamedical and health sciencesbasic medicinetoxicology Słowa kluczowe Nanotechnology Program(-y) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Temat(-y) LSH-2004-1.2.1-6 - Targeted delivery of protein-based drugs (especially orientated towards involvement of SMEs) Zaproszenie do składania wniosków FP6-2004-LIFESCIHEALTH-5 Zobacz inne projekty w ramach tego zaproszenia System finansowania STIP - Specific Targeted Innovation Project Koordynator FRAUNHOFER GESELLSCHAFT ZÜR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V Wkład UE Brak danych Adres Hansastrasse, 27 C MÜNCHEN Niemcy Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych Uczestnicy (8) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko UNIVERSITÉ DE LAUSANNE Szwajcaria Wkład UE Brak danych Adres Bâtiment du Rectorat et de l'Administration (BRA) LAUSANNE Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych UNIVERSITÉ DE BRETAGNE OCCIDENTALE Francja Wkład UE Brak danych Adres 3, rue des Archives BP 808 BREST Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Francja Wkład UE Brak danych Adres 3, rue Michel Ange PARIS Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych THE HEBREW UNIVERSITY OF JERUSALEM Izrael Wkład UE Brak danych Adres Mt Scopus JERUSALEM Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych AZIENDA OSPEDALIERA - OSPEDALI RIUNITI DI BERGAMO Włochy Wkład UE Brak danych Adres Largo Barozzi, 1 BERGAMO Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych MONOCLONAL ANTIBODIES THERAPEUTICS SAS Francja Wkład UE Brak danych Adres 5, rue Henri Desbruères EVRY Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych ALMA CONSULTING GROUP SAS Francja Wkład UE Brak danych Adres Domaine des Bois d'Houlbec 27120 HOULBEC-COCHEREL Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych MABGENE SA Francja Wkład UE Brak danych Adres Impasse des Chênes Rouge ALÈS Zobacz na mapie Linki Strona internetowa Opens in new window Koszt całkowity Brak danych
